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VAF347In binary cell-fate decisions, driving one lineage and suppressing the other are conjoined. We have
previously reported that aryl hydrocarbon receptor (AhR) promotes retinoic acid (RA)-induced gran-
ulocytic differentiation of lineage bipotent HL-60 myeloblastic leukemia cells. VAF347, an AhR ago-
nist, impairs the development of CD14+CD11b+ monocytes from granulo-monocytic (GM) stage
precursors. We thus hypothesized that VAF347 propels RA-induced granulocytic differentiation
and impairs D3-induced monocytic differentiation of HL-60 cells. Our results show that VAF347
enhanced RA-induced cell cycle arrest, CD11b integrin expression and neutrophil respiratory burst.
Granulocytic differentiation is known to be driven by MAPK signaling events regulated by Fgr and
Lyn Src-family kinases, the CD38 cell membrane receptor, the Vav1 GEF, the c-Cbl adaptor, as well
as AhR, all of which are embodied in a putative signalsome. We found that the VAF347 AhR ligand
regulates the signalsome. VAF347 augments RA-induced expression of AhR, Lyn, Vav1, and c-Cbl as
well as p47phox. Several interactions of partners in the signalsome appear to be enhanced: Fgr inter-
action with c-Cbl, CD38, and with pS259c-Raf and AhR interaction with c-Cbl and Lyn. Thus, we
report that, while VAF347 impedes monocytic differentiation induced by 1,25-dihydroxyvitamin
D3, VAF347 promotes RA-induced differentiation. This effect seems to involve but not to be limited
to Lyn, Vav1, c-Cbl, AhR, and Fgr.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction that enhance leukemic cell differentiation are sought to render RAAcute promyelocytic leukemia (APL) is a distinct form of acute
myeloid leukemia (AML) that is characterized by an arrest of
leukocyte differentiation at the promyelocyte stage. Standard
treatment of APL to mitigate the block includes differentiation
therapy with all trans-retinoic acid (RA) [1]. However, despite
advances in differentiation induction therapy and purported com-
plete remission rates of 80–85%, some APL patients develop either
relapsed or refractory disease which no longer responds to RA ther-
apy. Therefore, insights into novel pathways and molecular agentsefﬁcacious where it is presently not.
RA is a fundamental regulator of cell proliferation and dif-
ferentiation. It guides embryogenesis and controls differentiation
in processes such as immune response in mature animals, as well.
RA’s mechanism of action is thus of basic biological interest as well
as for therapy. Insights into how it elicits responses in non-APL cells
is thusof potential signiﬁcance to enhancing therapy. Aryl hydrocar-
bon receptor (AhR) is amultifaceted signaling transducer. As a tran-
scription factor, AhR is known to be involved in tumorigenesis and
proliferation of several stomach, breast, and liver cancers; further,
it has also been found to be implicated in cecal carcinogenesis and
even hematopoietic stem cell growth [2,3]. AhR is also known to
have several anti-tumorigenic effects and homeostatic regulatory
roles within the body, and it does so in a ligand agonist- or antago-
nist-speciﬁc manner [2,4,5]. In this regard, AhR can regulate tumor
cell differentiation to a non-tumor phenotype. However, it is not
yet clear whether AhR regulates such differentiation solely through
its classical transcriptional activity. In the case of retinoic acid (RA)-
induced granulocytic differentiation of human myeloblastic leuke-
mia cells, we reported that AhR promotes the RA-induced
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nuclear expression of stem cell transcription factor Oct4 [6].
Furthermore, other studies have reported AhR as a component of
an ubiquitin ligase complex involved in regulating the degradation
of select target proteins [7]. We also found that AhR can drive
cytoplasmic signaling via the Raf kinase of the MAPK pathways to
propel RA-induced differentiation of the leukemic cells [6]. Hence
AhRmay regulate tumor cells throughboth its classical nuclear tran-
scriptional role as well as cytoplasmic non-transcriptional
mechanisms.
AhR activity is regulated by ligands. It has been reported that
AhR’s transcriptional activity may be differentially elicited by
exogenous ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), or endogenous ligands such as the tryptophan metabolite
6-formylindolo (3,2-b) carbazole (FICZ) [8]. We previously
reported that FICZ also enhances RA-induced signaling events
and propels leukemic cell differentiation [9]. Therefore, AhR and
its ligands are attractive therapeutic targets for enhancing the
induction of leukemic cell differentiation [2], and mechanistic
insights of ligated AhR-regulated processes are likely to assist drug
development efforts. To this end, the effects of an AhR agonist
known as VAF347, i.e., (4-(3-Chloro-phenyl)-pyrimidin-2-yl)-(4-
triﬂuoromethyl-phenyl)-amine (Fig. 1), on signaling and RA-in-
duced cell differentiation and cell cycle arrest was analyzed
in vitro. VAF347 is a low molecular weight, cell permeable com-
pound that directly targets AhR with great afﬁnity and induces
downstream AhR signaling. This relatively novel compound causes
a number of anti-inﬂammatory responses in vitro and in vivo [10].
It inhibits the development of CD14+CD11b+ monocytes from gran-
ulo-monocytic (GM stage) precursors [11]. There is reason to sus-
pect that VAF347 may enhance the anti-cancer effects of RA.
Speciﬁcally, leukemic blasts that are differentiation-blocked at
the granulo-monocytic (GM) stage differentiate into neutrophils
upon RA exposure; whereas GM-precursors treated with 1,25-
dihydroxyvitamin D3 (D3) differentiate along the alternative
monocytic lineage. VAF347 has been found to inhibit monopoiesis
[11]. If driving one lineage and suppressing the other are conjoined
in binary fate decisions [12,13] then VAF347 might in fact propel
RA-induced granulocytic differentiation.
In the present study, the effect of VAF347 on RA-induced dif-
ferentiation and cell cycle arrest and the signaling events thought
to propel this were determined. It is known that the phenotypic
conversion elicited by RA is driven by an ensemble of signaling
molecules assembled in a signalsome [14–16]. The putative signal-
some incorporates in particular CD38 anchored c-Cbl and its
associated signaling partners, including c-Raf, Fgr, Lyn, Vav1 as
well as AhR. We demonstrate that VAF347 regulates Lyn, Vav1,
and c-Cbl, components of the signalsome, and enhances RA-in-
duced differentiation along the granulocytic lineage.
2. Results and discussion
2.1. VAF347 retards monocytic but enhances granulocytic
differentiation
VAF347 is an AhR agonist reported to hinder the development
of CD14+CD11b+ monocytes from precursors [11]. Based on theFig. 1. VAF347 structural formula. (4-(3-Chloro-phenyl)-pyrimidin-2-yl)-(4-tri-
ﬂuoromethyl-phenyl)-amine.paradigm that lineage bipotent cells excluded from one pathway
have enhanced differentiation along the alternative pathway, we
hypothesized that VAF347 might augment development of gran-
ulocytes from GM-precursors. Speciﬁcally, we tested the hypothe-
sis that VAF347 enhances the RA-induced differentiation of HL-60
myeloblastic leukemia cells. First, the effect of VAF347 on 1,25-
dihydroxyvitamin D3 (D3)-induced monocytic differentiation in
HL-60 was tested to assess if this model is concordant with the
in vivo mouse model where VAF347 inhibits differentiation to
monocytes. Flow cytometry analysis showed that administering
VAF347 concurrently with D3 signiﬁcantly inhibits the expression
of the monocytic differentiation antigen CD14, p < 0.02, (Fig. 2A)
compared to D3 alone, whereas expression of the monocytic-gran-
ulocytic integrin CD11b was not signiﬁcantly decreased (Fig. 2B).
VAF347 together with D3 does not signiﬁcantly augment the G0/
G1 arrest (Fig. 2C). VAF347 alone had no effect on any of these
three markers: CD14, CD11b or cell cycle arrest (Fig. 2).
Wright’s stain was used to assess the morphology of untreated,
VAF347 only, RA only, D3 only, VAF347 + RA, and VAF347 + D3 trea-
ted cells. As shown in Fig. 3, untreated HL-60 control and cells trea-
ted only with VAF347 consisted of undifferentiated blast cells with
frequent mitotic ﬁgures (Fig. 3, C and VAF). The remaining treat-
ments induced variable levels of morphologically detectable gran-
ulocytic or monocytic differentiation. None of these treatments
induced complete maturation to a segmented neutrophil, and cells
often retained nucleoli, which is typically a feature of immature
cells. However, HL-60 cells concurrently treated with vitamin D3
and VAF347 and those concurrently treated with RA and VAF347
(Fig. 3, D3 VAF and RA VAF) had differentiation detected in most
cells indicated by an indented or lobulated nucleus and a blue-gray
to pink cytoplasm color. Determination of whether this differentia-
tion was toward the granulocytic versus monocytic lineage is difﬁ-
cult based solely on morphology, but, interestingly, the treatment
with vitamin D3 plus VAF347 induced development of cells with
the most convincing granulocytic differentiation, i.e., cells with
clear to light pink cytoplasm. Cells treated with these combina-
tions also had very few undifferentiated blast cells and only rare
mitotic ﬁgures compared to other single agent treatments. The
morphological assessment agrees with the ﬂow cytometric mea-
surements in that VAF347 in combination with D3 does allow
initiation of the differentiation, but deters it from the monocytic
lineage.
HL-60 bipotent cells treated with RA differentiate along the
granulocyte lineage. In order to test whether or not VAF347
enhances this RA-induced differentiation toward the granulocytic
lineage and to determine the minimal concentration of VAF347
needed to elicit such a response, a dose response study was per-
formed at 48 h (Fig. 4A). Enhancement of RA-induced differentia-
tion was assessed by enhancement of two markers indicative of
RA-induced granulocytic differentiation: CD11b and cell cycle
arrest. Thus, cells were treated with either RA or RA with VAF347
at increasing concentrations of VAF347. We found that expression
of the CD11b membrane receptor (as determined from ﬂow
cytometry with a PE-conjugated antibody) was enhanced when
cells were co-treated with both RA and VAF347 at 100 nM com-
pared to RA alone (61% versus 53%, p = 0.006, after 48 h).
Furthermore, expression of the membrane receptor increased in a
dose dependent manner beyond 1 lM of VAF347 co-treatment
with RA.
Enrichment at G0/G1 was also examined for at 48 h (Fig. 4B).
Interestingly, G0/G1 was not enhanced at any combinatorial doses
under VAF347 at 20 lM co-treatment with RA. VAF347 at 20 lM
plus RA enhanced enrichment of G0/G1 compared to RA alone
(70.3% versus 60%, p = 0.01, after 48 h). Resultantly, we found that
RA with VAF347 at 20 lM when compared to RA alone was the
only treatment group that was signiﬁcant in enhancing both
Fig. 2. VAF347 inhibits D3-induced monocytic differentiation. HL-60 cells were initiated in culture with 0.5 lMD3, 20 lMVAF347 or both D3 plus VAF347 for 72 h when their
differentiation was analyzed. VAF347 in combination with D3 blunts the expression of (A) CD14 and (B) CD11b, and enhances (C) Cell cycle arrest at G0/G1. Percent increase of
expression of markers by D3 and/or VAF347 was set to exclude 95% of the control population for CD14 and CD11b. Means of treatment groups of interest were compared
using the Paired-Samples T Test. Data represent the means of three repeats ± S.E.M. A p-value of <0.05 was considered signiﬁcant.
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chose VAF347 at 20 lM as the concentration of interest for further
study in HL-60.
Induced expression of CD11b was subsequently measured at
72 h (Fig. 4C) of treatment. RA-induced CD11b expression was
lower than that induced by co-treatment with RA and VAF347
(50% versus 74%, p = 0.025, after 72 h). However, as determined
by ﬂow cytometry, combined RA- and VAF347-treated HL-60 cells
did not exhibit an increased cell surface expression of CD38
(Fig. 4D), an additional marker of RA-induced granulocytic dif-
ferentiation, compared to RA alone. CD38 levels remained
unchanged with VAF347 alone. The results found here are consis-
tent with previous work with an endogenous AhR ligand,
6-formylindolo (3,2-b) carbazole (FICZ) in myeloblastic leukemic
cells [9]. Here we ﬁnd that cells treated with VAF347 with RA dis-
played increased expression of cell surface marker CD11b.
However, CD38 expression at 7 h post treatment is decreased
(p = 0.018). Since CD38 is one of the earliest markers of progressivedifferentiation and CD11b is a later marker for a more differenti-
ated cell, differentiation was enhanced by VAF347, a suggestion
corroborated by growth arrest and RA-induced functional dif-
ferentiation betrayed by inducible oxidative metabolism, as shown
below.
Cell densities revealed the most pronounced growth retardation
due to co-treatment with RA and VAF347 (Fig. 4E). Corroborating
this, cell cycle arrest betrayed by enrichment of G0/G1 cells was
also enhanced by combined exposure to both RA and VAF347
(Fig. 4B, 48 h and Fig. 4F, 72 h). RA alone caused an increase in
the percentage of G0/G1 cells, and co-treatment further enhanced
cell cycle arrest (62% versus 78%, p = 0.011 after 72 h).
Corresponding reductions in S phase and G2 cells were also
observed. VAF347 thus enhanced RA-induced cell cycle arrest in
G1/0.
Enhanced induction of differentiation of human myeloblastic
leukemia cells by VAF347 is also shown by respiratory burst (indu-
cible oxidative metabolism), a functional marker of mature
Fig. 3. VAF347 promotes granulocytic morphology. HL-60 cells were initiated in culture with 20 lM VAF347 in combination with either 1 lM RA or 0.5 lM vitamin D3 for
96 h when cytocentrifuge samples were prepared and stained. C = untreated control cells; VAF = treated only with VAF347; D = treated only with vitamin D3; D VAF = treated
with vitamin D3 + VAF347; RA = treated only with retinoic acid; RA VAF = treated with RA + VAF347. C and VAF are composed of undifferentiated blast cells. The remaining
treatments induced variable levels of morphologically detectable granulocytic or monocytic differentiation, which are most easily detectable in the D VAF and RA VAF
treatments. Wright’s stain viewed with 500 magniﬁcation.
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neutrophils and macrophages to respond to bacterial infection, is
a functional differentiation marker of mature granulocytes and
monocytes. Accordingly, the ability of cells to undergo respiratory
burst was measured in RA and VAF347 treated cells. Respiratory
burst measured after treatment for 72 h was increased in cells trea-
ted with a combination of RA plus VAF347 compared to RA alone
(34% versus 13.4%, p = 0.046) (Fig. 4G). However at 48 h this differ-
ence was not yet signiﬁcant. In sum, VAF347 enhanced RA-induced
cell cycle arrest and myeloid differentiation. The representative
histograms for the assay reported in Fig. 4 are presented in
Figs. 5 (dose response) and 6 (phenotypic markers).
2.2. Modulation of signaling events driving differentiation by VAF347
RA-induced GM-precursor cell differentiation is driven by a
CD38 receptor anchored signalsome of MAPK signaling molecules;
ergo we next investigated if VAF347 augments RA-induced dif-
ferentiation via enhancement of the putative signalsome known
to be involved in directing the differentiation process in HL-60
cells. Important components of this signalsome that are upregu-
lated and/or activated following RA exposure include AhR, severalcomponents of the MAPK signaling cascade, Src-family kinases Lyn
and Fgr, and c-Cbl. The addition of VAF347 with RA augmented the
effects in particular on c-Raf, pS259c-Raf, (but notably not so for
MEK or ERK), on Vav1, and c-Cbl.
Western blot analysis showed (Fig. 7A) that RA induced
increased AhR levels compared to control, which correlates with
differentiation as reported in previous studies [9,17]. However,
adding VAF347 did not enhance this effect (Fig. 7A). RA alone,
VAF347 alone, and RA with VAF347 increased AhR expression to
a comparable extent. These ﬁndings are consistent with the notion
that enhanced effects attributed to VAF347 do not reﬂect enhanced
AhR expression but rather AhR’s activation.
Total c-Raf expression and its phosphorylation at pS259c-Raf
were increased by combination treatment, where addition of
VAF347 augments the increases caused by RA alone (Fig. 7A).
These results are consistent with previous reports of the upreg-
ulation of Raf and its activation by RA and the ability of Raf to drive
differentiation [18–22]. This may reﬂect an ability of VAF347 in
conjunction with AhR to regulate conformation of the signalsome
to enable the better signaling without necessarily altering stoi-
chiometry. It may also be a reﬂection of the previously reported
[22] RA-induced sustained activation of the signalsome that results
Fig. 4. VAF347 with RA enhances expression of differentiation marker CD11b, increases G0/G1 cell cycle arrest, and functional differentiation marker oxidative metabolism
(respiratory burst). HL-60 cells were exposed to either 1 lM RA or 1 lM RA with VAF347 at 10 nM, 100 nM, 1 lM, 10 lM, or 20 lM for the dose response studies at 48 h. Cells
were exposed to 1 lM RA, 20 lM of VAF347 alone, or both agents for further studies. Induced differentiation and cell cycle arrest were measured at the indicated times: 7, 48,
and 72 h. CD11b expression (as determined from ﬂow cytometry with a PE-conjugated antibody) was increased by combining both RA and VAF347 as opposed to RA or VAF
alone at: (A) 48 h and (C) 72 h (D) CD38 RA-induced expression (assayed with an APC-conjugated antibody) was decreased by VAF347. Gates were set to exclude 95% of the
control population to determine the percent increase in expression for tested cell surface differentiation markers. (E) Cell density was measured for treated and untreated HL-
60 cells at 0, 48, and 72 h. Cell growth showed that VAF347 was not toxic to the cells. G0/G1 cell cycle arrest is increased by co-administration of VAF347 and RA, compared to
RA alone. Cell cycle distribution of HL-60 cells exposed to RA, VAF347 or both agents was analyzed using propidium iodide stained nuclei. Percent of cells in G0/G1, S, and G2
is shown. An increase of cells in G0/G1 and corresponding decrease in S and G2 compared to RA alone was observed at (B) 48 h and (F) 72 h. Respiratory burst is augmented at
72 h by the combination treatment of RA with VAF347 compared to RA alone. Respiratory burst was quantiﬁed using ﬂow cytometry of dichloroﬂuorescein (DCF)-stained
cells. VAF347 with RA increased superoxide metabolites from inducible oxidative metabolism (p = 0.046) at (G). Gates were set to exclude 95% of DMSO population to
determine level of increased expression by VAF347. Statistical analyses were performed using GraphPad. Means of treatment groups of interest were compared using the
Paired-Samples T Test. Data represent the means of three repeats ± S.E.M. A p-value of <0.05 was considered signiﬁcant.
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Fig. 5. Dose response assay representative histograms. Representative histograms for CD11b PE and cell cycle for the studies quantiﬁed in Fig. 4A and B.
C.N. Ibabao et al. / FEBS Open Bio 5 (2015) 308–318 313in driving activated c-Raf to the nucleus; i.e., thereby redirecting
c-Raf from driving MEK/ERK in the cytoplasm.
Fgr and Lyn are two Src-family kinase members that have
been shown to be upregulated by RA in HL-60 cells [9].
Addition of VAF347 further increased expression of Lyn and Fgr,
compared to RA or VAF347 alone (Fig. 7A). VAF347 aloneincreased the expression of Lyn and Fgr when compared to
untreated control. The combined treatment with RA + VAF347
also increased the association of Fgr with CD38 and Fgr with
c-Cbl (Fig. 7B). VAF347 thus enhanced RA-induced effects on sig-
naling molecules thought to contribute to RA-induced differentia-
tion. VAF347 plus RA caused an association of AhR with Lyn that,




RA + VAF 
(20 µM) 
Fig. 6. Dose response assay representative histograms. Representative histograms for CD11b PE, CD38 APC, and cell cycle for the studies quantiﬁed in Fig. 4C, D and F.
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untreated or RA-treated cells (Fig. 7B). This interaction is different
from the aforementioned in that it is prominent and only detect-
able when both VAF347 and RA are present, suggesting a VAF347
dependent quantal, vs. incremental, conformational change in the
signalsome.
Expression of c-Cbl was upregulated by VAF347, and VAF347
augmented the RA induced increase (Fig. 7A). This is consistent
with the previously reported signiﬁcance of c-Cbl expression levels
to driving the RA-induced signaling that propels differentiation
[15,16,23]. Immunoprecipitation showed that RA increased the
interaction between c-Cbl and Fgr; and addition of VAF347 further
enhanced the amount of partnered c-Cbl and Fgr (Fig. 7B). These
ﬁndings are consistent with the notion that VAF347 can affect
the interaction of various signalsome components, suggesting a
signiﬁcant overall regulatory function for AhR in the signalsome.
This is furthermore corroborated by the ﬁnding that VAF347 with
RA enhanced AhR interaction with c-Cbl.
Vav1 expression is up regulated by RA and is further upregu-
lated by the addition of VAF347. By itself VAF347 also can upregu-
late Vav1. This is consistent with the known involvement of thisguanine nucleotide exchange factor in driving myelo-monocytic
differentiation. Vav1 is a requirement for RA-induced granulocytic
differentiation [24]. This further supports the ability of the VAF347
AhR ligand to regulate cytosolic signaling events that propel
differentiation.
VAF347 also upregulates the NADPH oxidase subunit of the
respiratory burst complex, p47phox, in the presence of RA, but
only very modestly as a single agent (Fig. 7A). Likewise, the
expression of p47phox appears to be particularly prominent in
cells treated with RA plus VAF347 versus RA alone. Since the
p47phox gene is transcriptionally regulated by AhR, the results
are consistent with VAF347 regulating AhR transcriptional activ-
ity in the nucleus. Upregulation of p47phox is a characteristic of
differentiated mature myeloid cells and an indicator of gran-
ulocytic differentiation, hence this ﬁnding supports the cytologi-
cal (Fig. 3) and phenotypic marker (Fig. 4G) results presented
earlier. While Fig. 7 presents the representative blots for western
blot analysis and immunoprecipitation, Fig. 8 presents the quan-
tiﬁcation of the western blots (normalized to untreated control)
and Fig. 9 presents the quantiﬁcation of co-IPs. Several quantiﬁed
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Fig. 7. VAF347 modulates RA elicited signalsome. HL-60 cells were cultured with 1 lM RA, 20 lM VAF347, or both agents. Whole cell lysates were collected after 48 h.
Lysates were resolved on a 12% polyacrylamide gel. 25 lg of protein was loaded in each well. GAPDH was used as the loading control for the western blot. (A) Western blot
assay of whole cell lysates. (B) Co-immunoprecipitation representative blots. Fgr or AhR associated complexes were immunoprecipitated from protein lysates of control, RA
alone, VAF347 alone, or both agents, using Fgr or AhR antibodies mentioned in Section 3. After the gel separation and membrane transfer, the co-immunoprecipitation was
probed for CD38, pS259c-Raf, or c-Cbl. AhR associations were tested with Lyn or c-Cbl antibodies. Fgr and AhR immunoprecipitations served as controls for Fgr and AhR total
amount pulled-down. Western blots and immunoprecipitation results are representative of at least three repeats.
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between replicates. Of signiﬁcance, the rank between treatment
groups is maintained across replicates.
In conclusion, the present study demonstrates that VAF347
enhances RA-induced differentiation of myeloid leukemia cells
toward the granulocytic lineage, and suppresses monocytic dif-
ferentiation. VAF347 enhanced signalsome activation, reﬂected in
expression, activation and interaction of its components; and
enhanced expression of cell surface marker CD11b, G0/G1 cell
cycle arrest, and respiratory burst. VAF347 appears to enhance sev-
eral signaling events seminal to RA-induced differentiation and
enhance the associated myeloid differentiation.
Taken together our results show that VAF347 enhances RA-in-
duced granulocytic differentiation and provide novel mechanistic
insights that might be exploitable for novel therapeutic modalities.
The indication that AhR has a cytosolic signaling regulatory func-
tion expands the classical paradigm of AhR as a nuclear transcrip-
tion factor. Combinatorial regimens incorporating VAF347 with RA
may enhance the therapeutic efﬁcacy of RA and expand its
chemotherapeutic efﬁcacy to diseases that are currently refractory
to RA.
3. Materials and methods
3.1. Cell culture and treatment
Stocks of HL-60 cells were grown in RPMI 1640 media
(Invitrogen, Carlsbad, CA) containing 5% heat inactivated FBS
(Hyclone, Logan, UT) and 1% of an antibiotic/antimycotic agent
(Invitrogen, Carlsbad, CA) in a 5% CO2 humidiﬁed atmosphere at
37 C. Cell growthand viabilitywere determinedbyhemocytometer
counts using 0.2% trypanblue (Invitrogen, Carlsbad, CA) exclusion to
assess cell viability. Cultures were initiated at a density of 0.2  106
cells/ml and subcultured to sustain densities not exceeding
2.0  106 cells/ml.For experimental cultures, two million HL-60 cells were derived
from a stock culture that never exceeded 1.2  106 cells/ml and
recultured in 10 ml fresh media. The cells were subsequently
exposed to retinoic acid (Sigma, St. Louis, MO, USA) or 1,25-
dihydroxyvitamin D3 (D3, Cayman, Mich., USA) dissolved in 100%
ethanol with a stock concentration of 5 mM and 1 mM, and used
at a ﬁnal concentration of 1 lM and 0.5 lM, respectively, and/or
(4-(3-Chloro-phenyl)-pyrimidin-2-yl)-(4-triﬂuoromethyl-phenyl)-
amine (VAF347, EMD Millipore, Billerica, MA) at a ﬁnal concentra-
tion of 20 lM. The VAF 347 was dissolved in DMSO for a stock
concentration of 10 mM.
3.2. CD38, CD11b, and CD14 quantiﬁcation
The expression of cell surface differentiation markers was quan-
tiﬁed using ﬂow cytometry. One million cells were centrifuged at
200 RCF for 5 min and then suspended in 200 ll PBS that contained
2.5 ll of a ﬂuorochrome-conjugated CD38, CD14 or CD11b anti-
body, as indicated in Section 2. After 1 h of incubation at 37 C with
the antibodies, samples were analyzed using a BD LSRII ﬂow
cytometer (BD, San Jose, CA). Allophycocyanin (APC) was excited
at 633 nm and emission was collected with a 660/20 band pass ﬁl-
ter. Phycoerythrin (PE) was excited at 488 nm and emission was
collected with a 585/42 band pass ﬁlter. Fluorescence intensity of
undifferentiated control cells was compared to treated cells.
Gates were set at 5% inclusion and 95% exclusion of the control
population as previously reported [6,9].
3.3. Cell cycle quantiﬁcation
One million cells were centrifuged and resuspended in 200 ll of
cold propidium iodide (PI) hypotonic staining solution containing
50 lg/ml propidium iodide, 1 mg/ml sodium citrate, and 1 ll/ml
Triton X-100 (all from Sigma, St. Louis, MO). Cells were incubated
at room temperature for 1 h and their nuclei were analyzed by ﬂow
Fig. 8. VAF347 signiﬁcantly modulates selected markers of the signalsome. Western blots quantiﬁcations was performed using Versa Doc Imaging Systems, Volume Analysis
Report, BioRad. Statistical analyses of all the repeats were performed using GraphPad. Means of treatment groups of interest were compared using the Paired-Samples T Test.
Data represent the means of at least three (and no more than ﬁve) repeats ± S.E.M. A p-value of <0.05 was considered signiﬁcant. For Lyn, Vav1, c-Cbl and p47phox, the
statistical signiﬁcance was reached (n = 5 repeats).
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lected through a 505 long pass dichroic mirror and a 575/26
band-pass ﬁlter. Doublets were identiﬁed by a PI signal width ver-
sus area plot and excluded from the analysis, as previously
described [25].
3.4. Respiratory burst quantiﬁcation
One million cells were centrifuged at 200 RCF for 5 min. Pellets
were suspended in 500 ll of PBS containing 5-(and-6)-chloro-
methyl-20,70-dichlorodihydro-ﬂuorescein diacetate acetyl ester
(DCF, Molecular Probes, Eugene, OR) with either DMSO carrier
blank solution or 12-0-tetradecanoyl-phorbol-13-acetate (TPA,
Sigma, St. Louis, MO) suspended in DMSO. Cells were incubated
for 25 min at 37 C and then analyzed by ﬂow cytometry aspreviously described [26]. Oxidized DCF was excited by a 488 nm
laser and emission was collected through a 505 long pass dichroic
mirror and a 530/30 nm band pass ﬁlter. The shift in ﬂuorescence
intensity in response to TPAwas used to determine the percent cells
with the capability to generate inducible oxidative metabolites.
Gates to determine percent positive cells were set to exclude 95%
of control cells not stimulated with TPA.
3.5. Western blotting and Immunoprecipitation
Whole cell lysates of HL-60 cells were prepared using 200 lL of a
Pierce M-PER lysis buffer solution (Pierce, Rockford, IL) containing
phosphatase and protease inhibitors (Sigma, St. Louis, MO).
Lysates were centrifuged at 16,000 RCF for 30 min. Protein lysates
were resolved by gel electrophoresis and transferred onto
Fig. 9. VAF347 tends to augment subcomponents of the signalsome. Western blots quantiﬁcations of the proteins associated (directly or indirectly) with either Fgr or AhR
antibodies were performed using Versa Doc Imaging Systems, Volume Analysis Report, BioRad. Statistical analyses of all the repeats were performed using GraphPad. Means
of treatment groups of interest were compared using the Paired-Samples T Test. Data represent the means of four repeats ± S.E.M. A p-value of <0.05 was considered
signiﬁcant.
C.N. Ibabao et al. / FEBS Open Bio 5 (2015) 308–318 317Immobilon-P PVDF membrane (Millipore Corporation, Billerica
MA). Equal amounts of protein lysates (25 lg) were resolved by
SDS-PAGE gel electrophoresis. For immunoprecipitation, equal
amounts of protein (250 lg) were preclearedwith 30 lL of A/G pro-
tein beads (Santa Cruz Biotechnology, Santa Cruz, CA). Lysates were
then treated 1/100 volume of antibody and 50 lL of beads overnight
at 4 C prior to electrophoresis. Blots were probed with antibodies:
AhR (H211), c-Cbl (C-15)- (Santa Cruz Biotechnology, Santa Cruz,
CA); CD38 (BD Biosciences, San Jose, CA); phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204) (D13.14.4E), p44/42 MAPK (ERK1/2)
(137F5), pS221 MEK1/2, MEK1/2, Lyn, Fgr, Vav1, p47phox, c-Raf,
pS259c-Raf, GAPDH (Cell Signaling, Danvers, MA). Horseradish
peroxidase anti-mouse and anti-rabbit antibodies (Cell Signaling,
Danvers, MA) and ECL (GE Healthcare, Pittsburgh, PA) were used
during detection. Blots were repeated at least three times.
3.6. Wright’s-staining
HL-60 cells were treated for 96 h with combinations of RA,
VAF347, and vitamin D3 as described above. Cytocentrifuged ali-
quots of control and treated cells were prepared and stained with
a modiﬁed Wright’s stain using an automated stainer (Hema-Tek,
Siemens, Germany). The slides were assessed for morphologic
characteristics of granulocytic and monocytic differentiation.
Undifferentiated blast cells were identiﬁed as cells with a highnuclear:cytoplasmic ratio, a round nucleus, prominent nucleoli,
and small to moderate amounts of dark blue cytoplasm.
Granulocytic or monocytic differentiation was noted if the nucleus
was deeply indented or lobulated. Differentiating early gran-
ulocytic from monocytic differentiation based solely on morphol-
ogy of the cells is difﬁcult, but the cytoplasm of granulocytic
cells will become pink to clear as the cell matures. Differentiated
monocytic cells have a cytoplasm that is typically blue-gray, but
can sometimes have ﬁne pink granules that can give the cytoplasm
a pinkish hue when viewed using a Romanowsky stain [27,28] .
3.7. Statistics
Statistical analyses were performed using Excel and GraphPad
(GraphPad software, San Diego, CA). Means of treatment groups
of interest were compared using the Paired-Samples T Test. Data
represent the means of three repeats ± S.E.M. A p-value of <0.05
was considered signiﬁcant.
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